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ABSTRACT: Jumonji domain-containing lysine demethylase
(KDM) enzymes are encoded by genes of the KDM superfamily.
Activities of the KDM4 subfamily promote aggressive phenotypes
associated with prostate cancer (PCa). Previously, we discovered a
benzimidazole pyrazole molecule that inhibited KDM4 isoforms
with properties tractable for development. Here, we demonstrate
that a benzyl-substituted variant of this inhibitor exhibits improved
potency in biochemical assays, is cell-permeable, and kills PCa cells
at low micromolar concentrations. By X-ray crystallography and
kinetics-based assays, we demonstrate that the mechanism of
inhibition is complex, proceeding via competition with the enzyme
for binding of active-site Fe2+ and by populating a distal site on the
enzyme surface. Furthermore, we provide evidence that the
inhibitor’s cytostatic properties arise from direct intracellular inhibition of KDM4 enzymes. PCa cells treated with the inhibitor
exhibit reduced expression of genes regulated by the androgen receptor, an outcome accompanied by epigenetic maintenance of a
heterochromatic state.
■ INTRODUCTION
Over the last several years, lysine demethylase (KDM)
enzymes have gained recognition as targets for drug-mediated
therapy against various diseases and ailments ranging from
cancer,1 inflammation,2 and viral infection.3−5 Originally, and
within a clinical context of prostate cancer (PCa), the flavin
adenosine dinucleotide (FAD)-dependent KDM1 demethylase
was demonstrated to directly interact with nuclear-localized
androgen receptor (AR),6 stimulating gene transcription by
removing repressive mono- and di-methyl epigenetic marks at
lysine 9 of histone H3. Subsequent reports expanded upon
histone demethylation activities by demonstrating that iso-
forms of the KDM4 subfamily (KDM4A, KDM4B, KDM4C,
and KDM4D) also interact with the nuclear-localized AR7−9
and stimulate gene transcription by removing repressive di-
and tri-methyl epigenetic marks at lysine 9 of histone H3 (the
latter of which is denoted here as H3K9me3). Since these
discoveries, several additional KDMs have been identified,
whose collective activities are now recognized as important
mediators of disease progression. Accordingly, many KDMs
are current targets of small-molecule discovery campaigns with
hopes that inhibitors found therein may prove to be of
therapeutic value.1−5
The KDM4 subfamily (KDM4A-E) belongs to a larger
superfamily of enzymes referred collectively as the jumonji C
(JmjC) domain-containing KDMs (denoted here as JmjC-
KDMs). All members of this superfamily utilize Fe2+ as a
cofactor and α-ketoglutarate [α-KG or 2-oxoglutarate (2OG)]
as a cosubstrate to demethylate specific lysine residues within
core histones of nucleosomal assemblies.10 These activities are
believed to stimulate gene transcription by participating in a
complex process of chromatin reorganization, ultimately
yielding an expanded state of euchromatin, opened to initiate
gene transcription. In doing so, nuclear transcription factors
gain access to promoters of genes they regulate, thereby
initiating general transcription. Some of these KDM-regulated
genes act as oncogenes, endowing cancer cells with
proliferative advantage.11
To date, several inhibitors targeting JmjC-KDMs have been
described (reviewed extensively in refs 12−15). Most of these
inhibitors competitively interfere with substrate turnover by
acting as inert α-KG surrogates. Notable exceptions include
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JIB-04, which was described to inhibit the KDM4 subfamily via
a non-competitive mechanism with respect to α-KG,16 as well
as peptidomimetics designed to mimic the histone substrate.17
Previously, we reported the results of a high-throughput screen
(HTS) against the human KDM4E isoform and the
identification of a novel benzimidazole-pyrazole scaffold with
properties tractable for further development.18 In addition to
these properties, the scaffold was notable in that it shared
similarities with two compounds developed as competitive
inhibitors of other Fe2+/α-KG-dependent enzymes.19,20
However, although this benzimidazole pyrazole compound
functioned in orthogonal, biochemical-based assays of KDM4
activity, it exhibited limited anti-proliferative activity in cell-
based models of PCa and KDM4 function.
Here, we report on efforts to enhance the properties of this
scaffold, resulting in a compound with 10-fold increased
potency relative to the original HTS hit, and via a complex
mechanism of action, coupling a competition with the enzyme
for active-site Fe2+ with binding to a distal, as-of-yet
undescribed site on the enzyme’s surface. We demonstrate
that the improved scaffold is cell-permeable and provide
several lines of evidence for the inhibition of KDM4 enzymes
in PCa cell lines. Importantly, inhibition of intracellular KDM4
activity coincides with the accumulation of the repressive
H3K9me3 epigenetic mark and down-regulation of genes
expressed during PCa progression. These results provide the
proof of principle that the molecular scaffold merits further
investigation and optimization as an in vivo KDM4-specific
inhibitor.
■ RESULTS
Enhanced Efficacy of the Benzimidazole Pyrazole
Scaffold. Our previous efforts18 identified molecule CBN
209350, a novel benzimidazole pyrazole-based inhibitor of
recombinant KDM4E, from a high-throughput screen. This
compound inhibited equally all members of the KDM4 family
and exhibited modest selectivity over other JmjC-KDMs
including KDM2A and PHF8. We hypothesized that the
compound inhibited these enzymes in part by chelating active-
site Fe2+ and envisioned a similar mode of binding as observed
in two crystal structures of inhibitor-bound KDM4A (PDB-ID
4URA21 and PDB-ID 4GD422).
Notably absent from CBN 209350, but present in several
other competitive JmjC-KDM inhibitors, were sidechains
capable of forming canonical hydrogen bonds with residues
comprising the enzyme’s active site (described extensively in
ref 15). The importance of this H-bonding motif is
underscored by several inhibitors possessing either a
carboxylate function12−15 or a similar bioisostere23 and
which mimic the terminal ethyl carboxylate found in the
cosubstrate, α-KG. We hypothesized that a similarly positioned
carboxylic function in the pyrazole scaffold might mediate such
interactions. To test this, an optimization campaign was
initiated by synthesizing derivatives of CBN 209350 (denoted
hereafter as compound 1, Table 1) with functionalized
sidechains containing carboxyl moieties or ester variants
thereof. The initial design strategy (compounds 2−6, Table
1, Figures 1 and S1) incorporated these functionalized
sidechains at positions R1 and R2 of the original scaffold, so
that they might participate in canonical H-bonding interactions
with JmjC-KDM active-site residues Tyr132 and Lys206
(human KDM4A numbering). These and all further
compounds were then tested as inhibitors of KDM4E, a
model isoform of KDM4 enzymes, which by our handling
displayed the greatest activity in biochemical assays.
Compound synthesis proceeded via condensation of differ-
ent 2-hydrazineyl-1H-benzimidazoles and β-keto-esters sub-
stituted at the 2- and 3-positions (Scheme 1). Longer
sidechains of β-keto-esters at the 3-position were synthesized
by an aldol-reaction between methyl-phenylacetate and
corresponding aldehydes, followed by Swern oxidation or
Table 1. Synthetic Derivatives of a Benzimidazole Pyrazole-
Based JmjC-KDM Inhibitor
aValues calculated from kinetic data using the log(inhibitor) vs
response−variable slope inhibition model in GraphPad Prism. See
Table S1 for full fitting statistics. bValues from the FDH-based assay.
cValues from the CTH ELISA-based assay. dData reproduced from
Carter et al.18: values of IC50 = 12.5 and 800 μM when fit to a
biphasic inhibition model. eNo inhibition seen at the highest
concentration of inhibitor tested.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c00693
J. Med. Chem. 2021, 64, 14266−14282
14267
oxidation with the Dess-Martin reagent. This condensation
resulted initially in the formation of 2-(1H-benzimidazol-2-yl)-
2,4-dihydro-3H-pyrazol-3-one derivatives, which in some cases
were detected as intermediates. However, under reflux in
EtOH, the more stable aromatic 1-(1H-benzo[d]imidazol-2-
yl)-1H-pyrazol-5-oles were identified and isolated as the final
products.
Surprisingly, compounds 2−6 were less potent than the
resynthesized HTS hit (compound 1; IC50 = 15 μM, Table 1).
Moreover, the less polar ester derivatives exhibited greater
potencies than their free-acid counterparts (Table 1, compare
compound 1, IC50 = 15 μM, with compound 2, IC50 = 347
μM; compound 3, IC50 = 72 μM, with compound 5, IC50 =
274 μM; and compound 4, IC50 = 106 μM, with compound 6,
IC50 = 437 μM).
Outside of the canonical H-bonding interactions by which
α-KG surrogates participate, crystal structures of KDM4A24
with bound synthetic methyl-lysine peptides (PDB IDs 2OT7,
2OQ6, 2OX0) revealed additional recognition motifs exploit-
able by rational inhibitor design. For example, the positively
charged tri-methyl nitrogen from the lysine sidechain of a H3-
derived peptide (H3K9me3) forms cation−π interactions with
residue Tyr175 and possibly Tyr177 in the KDM4A substrate-
binding pocket.24 We therefore considered that incorporation
of a substituted amino sidechain into compound 1 might
occupy a similar space in KDM4E, contributing toward
enhanced potency (Figure 1). In total, four compounds were
synthesized and assessed for inhibitory efficacy (Table 1,
compounds 7−10, Figure S2). Initially, compound 5 was
amidated with methylamine and dimethylamine to yield
compounds 7 (IC50 = 41 μM) and 8 (IC50 = 16 μM); both
compounds inhibited KDM4E with greater potency compared
to the corresponding ester (compound 5, IC50 = 72 μM).
Compounds 7 and 8 were then further reduced with a borane
dimethylsufide complex to yield terminal mono- and di-
substituted amines 9 and 10. Reduction of compound 7 to 9
(IC50 = 9 μM) enhanced KDM4E inhibition, although with a
potency similar to the original resynthesized HTS hit.
Conversely, reduction of compound 8 to 10 (IC50 = 70 μM)
weakened the potency of KDM4E inhibition.
Taken together, these results indicated that less polar ester
and amide variants are more potent KDM4E inhibitors than
their free carboxylic acid counterparts. To expand upon this,
compounds 11−15 were generated and a progression toward
greater potency was observed as the sidechain at position R2
became less polar (Table 1, Figure S3). In the absence of a
sidechain at this position (compound 11), the scaffold
exhibited an IC50 of 76 μM. The addition of allyl and alkyl
sidechains at this position (compounds 12 and 13,
respectively) afforded similar increases in potency (IC50 values
of 24 μM for both compounds). However, potency increased
further upon introduction of an alkyne sidechain at this
position (compound 14; IC50 = 5 μM) and reached its highest
potency upon introduction of an aromatic ring (compound 15;
IC50 = 871 nM, Figure 2A).
Given the notable preference for nonpolar, electron-rich
sidechains at position R2, we further assessed whether the
length of such substitutions influenced the potency of KDM4E
inhibition (Table 1, compounds 16−17, Figure S4). Extension
of the benzyl sidechain (compound 16; IC50 = 27 μM)
decreased the potency compared to that of compound 15, as
did the addition of a methyl group para to the benzyl-pyrazole
conjugation (compound 17, IC50 = 27 μM). Expanding upon
this, whether incorporation of additional nonpolar sidechains
into compound 15 affected inhibitor potency (Table 1,
compounds 18−19, Figure S4) was then assessed. Potency
diminished slightly when ethyl or butyl sidechains were
introduced at position R1 next to the favored benzyl
substitution (compounds 18 and 19; IC50 values of 5 and 6
μM, respectively).
The role of the hydroxyl moiety attached to the pyrazole
ring was also characterized (Table 1, compounds 20−23,
Figure S5). Accordingly, neither a brominated derivative of the
original scaffold lacking this hydroxyl group (compound 20)
nor a methyl-substituted variant, rabenzazole (compound 21),
inhibited KDM4E at concentrations up to 100 μM. Similarly,
an amino analogue (compound 22) exhibited weakened
potency (IC50 = 199 μM) relative to its hydroxylated variant
(compound 11, IC50 = 76 μM), and compound 23, an
aminated variant of compound 15, also exhibited weakened
potency (IC50 ∼ 160 μM). Taken together, these data
indicated that the pyrazole hydroxyl moiety is an essential
Figure 1. Binding-site regions targeted in JmjC-KDM active sites. The
catalytic domain of human KDM4A is depicted in cartoon
representation in the bottom figure (PDB code 4V2V); an active-
site close-up is enlarged in the box at the top and depicted in gray
surface representation. The cosubstrate α-KG is depicted in stick
representation and colored by atom. The tri-methylated epsilon
nitrogen moiety of lysine 9 within the H3K9 histone side-chain is
depicted in ball-and-stick representation and colored by atom. Active-
site Fe2+ is depicted as a green sphere. The region outlined by the red
dashed line represents active-site regions targeted by carboxy-
substitutions within the inhibitor scaffold (compounds 1−6 and
30). The region outlined by the yellow dashed line represents active-
site regions targeted by substituted amines within the inhibitor
scaffold (compounds 7−10).
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determinant underlying the compounds with enhanced
inhibitory efficacies.
Previously, we hypothesized that inhibition of KDM4
enzymes by compound 1 proceeds in part via chelation of
active-site Fe2+ by the bidentate heterocyclic nitrogen atoms
embedded within the scaffold.18 To characterize metal
chelation, two derivatives of compound 15 were generated
(Table 1, Figure S6) which lack tautomerism in the
benzimidazole, including compound 24 (IC50 = 35 μM),
which replaces the benzimidazole NH moiety with a sulfur
atom, and compound 25 (IC50 = 34 μM), which methylates
the NH moiety. Both substitutions reduced potency compared
to compound 15. Although nucleophilicity between 15 and 25
is similar, the conformation might be influenced by steric
hindrance between the pyrazole ring’s methyl and hydroxyl
groups, leaving 25 in a nonplanar conformation detrimental for
Fe2+ chelation. For compound 24, the sulfur atom might partly
contribute as an alternative Fe2+ chelation motif. Although
sulfur-containing molecules are known chelating agents, sulfur
atoms in heteroaromatic rings have a poor coordinating ability
due to the pseudo aromatic nature of the ring, causing the lone
pair to be less available for donation and the π-orbitals less
capable of accepting electrons from a metal.
To characterize the contribution of the scaffold’s benzimi-
dazole moiety toward potency of KDM4E inhibition, it was
exchanged (Scheme 2, Table 1, Figure S7) with a pyridine
(compounds 26−28; Table 1, IC50 values = 74, 57, and 191
μM, respectively) or with a 3-chloro pyridazine (compound
29; Table 1, IC50 = 68 μM), while leaving the favored pyrazole
substitutions as found in compounds 12, 15, and 16 (IC50
values = 24 μM, 871 nM, and 27 μM, respectively). Notably,
all variants were less potent than the respective benzimidazoles
with a qualitative agreement between IC50 rankings derived
from the phenyl pyrazole substitution. Taken together, these
data indicated that inhibitor potency is not solely dependent
on the nature of the heterocycle as long as it contains an
aromatic nitrogen atom for the bidentate chelation motif.
Finally, whether modifications such as a carboxylic acid
functional group attached to the benzimidazole moiety affected
inhibitor potency were characterized. Our reasoning originated
from a hypothesis that the initial position of the carboxylic acid
on the pyrazole moiety (i.e., the R1 and R2 scaffold positions)
was not optimized. Upon rotating by 180° in the active site,
the inhibitor’s benzimidazole-substituted carboxylic acid might
therefore interact with active side residues Tyr132 and Lys206,
leading to strong hydrogen bond interactions. In testing this
hypothesis, compound 30 was synthesized, which inhibited
KDM4E with an IC50 value of 20 μM (Table 1, Figure S8).
Although the potency of 30 was weakened relative to 15, its
solubility was greatly enhanced, an important feature that was
subsequently leveraged in crystallization experiments (dis-
cussed below). Taking into consideration all of the SAR data
presented above, we concluded that compound 15 was most
improved with respect to the original HTS hit and with several
properties warranting further investigation as described below.
Orthogonal Activity of the Optimized Scaffold. As an
orthogonal test of enzyme activity, we utilized an ELISA-based
method that we developed and described previously.18 This
assay measures the methylation state of core histones purified
from calf thymus, directly as the readout. Concentration-
dependent responses were observed when compound 15 was
titrated into a solution of KDM4E prior to histone
demethylation. In general, the IC50 measured from this
method (13 μM, Table 1) agreed within an order of magnitude
Scheme 1. General Synthesis of Benzimidazole Pyrazoles
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with values measured by the FDH assay, confirming that the
derivative is more potent than the original HTS hit (Table 1
and Figure 2B).
Mechanism of Inhibition. The mechanism by which
compound 15 inhibits KDM4E was subsequently evaluated
using initial velocity data from the FDH assay to calculate
cofactor and substrate-derived values of Km and Vmax. These
experiments were then repeated to assess how the kinetic
constants changed in the presence of an inhibitor. In an initial
control experiment, whether compound 15 inhibits the FDH
coupling enzyme was assessed. As expected, neither the
original HTS hit, nor compound 15, inhibited FDH in the
concentration ranges tested (Figure S9). Next, as an additional
control to validate the experimental setup, we assessed how
KDM4E kinetic constants were affected by the well-
characterized JmjC-KDM competitive inhibitor, 2,4-PDCA.
Accordingly, a competitive inhibition profile was observed in
the measured kinetic data with respect to the cofactor, α-KG.
In the absence of the inhibitor, an α-KG-dependent Km value
of 22 μM was calculated, increasing to 69 μM in the presence
of 2,4-PDCA, as would be expected for a competitive inhibitor
(Figure 2C, Table 2). In parallel, α-KG-dependent Vmax values
remained unaffected by the presence of this inhibitor (42 and
37 s−1 in the absence and presence of 2,4-PDCA, respectively).
By contrast, results pertaining to the inhibition of KDM4E
by compound 15 suggested a complex mechanism of
Figure 2. Kinetic analyses of KDM4E inhibition. (A) Fluorescence-based, FDH-coupled KDM4E activity profiles. Comparison of enhanced
KDM4E inhibition via compound 15 (red) compared to the initial HTS hit, compound 1 (blue). (B) CTH ELISA-based KDM4E inhibition
profiles. Comparison of enhanced KDM4E inhibition by compound 15 (red) relative to the HTS hit, compound 1 (blue). (C) Determining a
mechanism of action for the inhibition of KDM4E by 2,4-pyridinedicarboxylic acid (2,4-PDCA). Depicted in the top panel are Michaelis−Menten
fits used to determine Km and Vmax values of α-KG in the presence of zero (green), 1 μM (blue), or 5 μM (red) 2,4-PDCA. Double reciprocal plots
of these same data are depicted below. (D,E) Determining a mechanism of action for the inhibition of KDM4E by compound 15. Depicted in the
top panels are Michaelis−Menten fits used to determine Km and Vmax values for peptide substrate H3K9me3 (panel D) and for α-KG (panel E),
respectively. Kinetic constants were determined in the presence of either zero (green), 1 μM (blue), 5 μM (orange), or 10 μM (red) compound 15.
Double reciprocal plots of these same data are depicted below each panel accordingly.
Scheme 2. Synthesis of Pyridine Pyrazolesa
aConditions and reagents: (a) EtOH, reflux, 2 h.
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inhibition, differing with respect to the cofactor/(co)-substrate
under investigation. For example, with respect to the
H3K9me3 peptide substrate, increasing concentrations of 15
decreased the values of Vmax with no effect on this substrate’s
Km (Figure 2D, Table 2). This suggests a non-competitive
mechanism of inhibition, whereby the binding sites of
compound 15 and peptide substrate do not overlap; 15 can
bind to the enzyme whether or not the peptide substrate is
bound. Conversely, with respect to the α-KG cofactor,
increasing concentrations of 15 caused concomitant decreases
in both Vmax and Km (Figure 2E, Table 2). These data suggest
that compound 15 is uncompetitive with respect to the α-KG
cosubstrate. One interpretation of this outcome25 follows that
binding of 15 favors the formation and stabilization of a
KDM4E:α-KG complex (decreasing the Km) but that this
stabilized complex is less primed for substrate turnover
(decreasing the Vmax). Although an uncompetitive inhibitory
mechanism was not expected, structural investigations into the
mode of binding support this interpretation, as further
described below.
Crystal Structures of Compounds Bound to KDM4A.
The kinetics-based investigations into the mechanism of action
(MOA) for the inhibition of KDM4E by 15 suggested a
complex mechanism, corroborating challenges faced in the
optimization campaign. We therefore sought to further
investigate this mechanism by determining crystal structures
of the engineered compounds bound to a JmjC-KDM enzyme.
In doing so, we succeeded in determining two crystal
structures of the KDM4A isoform (PDB IDs 6G5W and
6G5X) with bound derivatives (compounds 26 and 30) of the
original HTS hit (Figure 3A−C, Table S2). Both structures
revealed an unexpected and novel binding site, not yet
described in other inhibitor/fragment-bound structures of
JmjC-KDM enzymes. In these structures, the inhibitors were
observed bound to an identical surface-exposed binding site on
a single KDM4A protein molecule (chain B), close to the
intermolecular interface of molecules in the asymmetric unit.
By comparison to the apo-enzyme, KDM4A’s Phe114
sidechain rotates approximately 90°, translocating its phenyl
moiety a distance of 4 Å, and opening a small hydrophobic
pocket comprising residues Glu118, Ser207, Tyr209, Thr261,
Lys259, Phe279, plus the aforementioned Phe114 (Figure
3B,C). This pocket is occupied in both structures by the
phenyl moieties that constituted favored substitutions within
the scaffold’s R2 position. In both structures, the ligands’
pyrazole moieties interact via CH−π interactions26 with
KDM4A’s Phe114 sidechain ring, while the pyrazole hydroxyl
group forms hydrogen bonds with a main-chain N atom and a
hydroxyl group of Thr261. By contrast, distal moieties of both
ligands project into the surrounding solvent between both
KDM4A protein molecules of the asymmetric unit. These
moieties comprise a pyridine ring in compound 26 and a
benzimidazole in compound 30. In the latter case, the
benzimidazole aligns linearly with a guanidine moiety of
Arg218 from a KDM4A protein in chain A with a distance of
about 3.5 Å, suggesting a cation−π interaction. Conversely, the
pyridine moiety of compound 26 is not involved in a protein−
ligand interaction. Importantly, both inhibitors chelate a Ni2+
ion (added to crystallization buffers as an Fe2+ surrogate)
whose coordination is completed by a citrate molecule that was
present in the crystallization solution (Figure 3B,C).
KDM4 Inhibitor Scaffolds Displace Active-Site Metal
Ions. Our previous kinetics-based mechanistic evaluations
using KDM4E and compound 15 suggested a complex MOA
that was non-competitive with respect to α-KG. Although this
outcome was unexpected, the crystal structures presented here
also revealed that inhibitors based on the original HTS scaffold
can still interact with Fe2+ and that this property is an essential
determinant of inhibition. Although both structures revealed
inhibitor molecules bound to KDM4A’s distal surface-exposed
hydrophobic pocket, the active sites remained occupied by
Ni2+ ions, together with citrate molecules from the
crystallization buffer. The presence of active-site Ni2+ was
not surprising since saturation of the enzyme’s active site
necessitated the soaking of crystals in solutions containing a
molar excess of this ion. Because KDM4A crystals are fragile,
require manipulation in cold-room conditions, and frequently
suffer from loss of diffraction quality, surrogate KDM4
isoforms were considered for subsequent crystallographic
analysis. Accordingly, the KDM4D isoform crystallizes at
room temperature and under conditions that can be altered,
often with no apparent loss in diffraction. For these reasons,
KDM4D crystals were soaked in a solution containing Ni2+
ions at molar excess, followed by a second soaking in a solution
containing the original HTS hit (compound 1 alone, without
additional Ni2+ ions). Although KDM4D crystals were soaked
in the presence of several benzimidazole pyrazole inhibitors,
including those identified in KDM4A crystal structures, most
soaking experiments led to complete loss of diffraction.
However, KDM4D crystals soaked with compound 1, as
described above, diffracted up to 1.5 Å resolution. The
resulting structure (data not shown) revealed no electron
density for the ligand in the active site, nor for the active-site
Ni2+ ion. When present, this ion coordinates to KDM4D
Table 2. Kinetic Constants of KDM4E Activity in the Presence of Selected JmjC-KDM Inhibitors
KDM4E cosubstrates and kinetic constants
α-KG H3K9me3
inhibitor test concentration (μM) Km (μM)
a Vmax (s
−1)a Km (μM) Vmax (s
−1)
2,4-PDCA 0 22 [16−28]b 42 [39−45] NDc ND
1 69 [52−85] 37 [33−41]
5 NAd NA
cmpd 15 0 12 [10−14] 35 [33−37] 11 [10−13] 21 [20−22]
1 13 [11−15] 31 [30−32] 14 [13−16] 21 [21−22]
5 8 [6−9] 24 [22−25] 14 [12−17] 14 [14−15]
10 2 [1−2] 12 [11−14] 19 [14−24] 5 [5−6]
aDetermined from the best fits of the Michaelis−Menten model in GraphPad Prism to the initial velocity data. bValues in brackets represent the
95% confidence interval from the best fits of the Michaelis−Menten Model. cNot determined. dKinetic data did not reach a point of substrate
saturation required for accurate estimations of the kinetic constant.
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active-site residues His192, Glu194, and His280, with bond
distances ranging between 2.1 and 2.2 Å. Electron density
within this active-site region was generally weak and barely
sufficient to model a Ni2+ ion with about 10% occupancy. Since
the magnitude of this signal was too small for modeling into
the structure, we omitted it from the final refined model.
Instead, a water molecule was modeed, which forms hydrogen
bonds with distances of 2.6 and 2.7 Å to KDM4D residues
His192 and Glu194, respectively.
To quantify the presence of Ni2+ ions in KDM4D crystals
before and after ligand-soaking experiments, energy-dispersive
fluorescence spectra were collected. Peak heights of three
replicate measurements were averaged and normalized to a
single representative measurement based on the highest
observed peak (corresponding to a structural, non-catalytic
zinc atom present in all KDM4 enzymes). Although the
magnitude of the Ni peak decreased from 0.74 to 0.12 au after
soaking with compound 1 (Figure 3D), it remained unchanged
after soaking with DMSO (Figure 3E, magnitudes of 0.66 and
0.64 before and after soaking with DMSO, respectively).
Taken together, these data unequivocally demonstrated that
the benzimidazole pyrazole inhibitor is capable of completely
removing active-site metal ions, thereby inactivating the
enzyme.
Cytotoxicity of the Improved KDM4 Inhibitor. Another
goal of the discovery campaign was to increase cellular
penetration of the KDM4 inhibitor scaffold in order to assess
whether derivatives might inhibit the enzymes in relevant
cellular models of PCa. The original scaffold identified in the
HTS campaign (compound 1) exhibited only limited activity
in cytotoxicity assays (GI50 = 410 μM against the LnCaP cell
line).18 Extending from this, the alamarBlue assay was
employed to assess the viability of PCa cells treated with the
improved KDM4E inhibitor, compound 15. Accordingly,
compound 15 was found to be more potent than both the
parent scaffold (Table 3 and Figure 4A) and ML324, another
cell-permeable JmjC-KDM inhibitor.27 The resulting cytotox-
icity profiles (Figure 4B) indicated that 15 inhibited the
growth of all PCa cell lines tested, including DU145 cells and
PC3 cells, plus a non-disease control cell line (HuPrEC), with
similar efficacies and values of GI50 in the range of 8−26 μM
(Table 3).
Figure 3. Structural insight into the inhibition of the KDM4
subfamily of enzymes by pyrazole imidazole-based compounds 26 and
30. (A) Crystal structure of KDM4A (ribbon representation) with
compound 26 (stick representation) bound between two molecules of
the asymmetric unit. Nickel ions are indicated as cyan spheres. A
citrate molecule (stick representation) is also shown. (B,C) Detailed
views of KDM4A inhibitor binding sites. Electron densities (Fo − Fc
maps contoured at 1.0 σ for 26 and at 1.5 σ for 30) of the inhibitors
bound to the surface of KDM4A are indicated by the mesh. Inhibitor
compounds 26 (panel B) and 30 (panel C) are indicated in stick
representation along with additionally bound citrate molecules.
Sidechains of KDM4A residues (green stick representation)
comprising the inhibitor binding site are labeled accordingly. (D,E)
Energy-dispersive fluorescence spectra demonstrating the removal of
Ni2+ ions from the active sites of KDM4D crystals. Peaks arising from
metal ions present in the crystals are labeled accordingly. Crystals
were first soaked in a molar excess of Ni2+ ions, and the resulting
fluorescence spectra were recorded (blue spectra in panels D and E).
These same crystals were then soaked overnight either in a solution
containing KDM4 inhibitor compound 1 (red spectrum, panel D) or
a control solution containing buffer plus DMSO alone (green
spectrum, panel E). Disappearance of the Ni2+ peak in inhibitor-
soaked crystals indicates the removal of this ion from the protein
molecules.
Table 3. Cytotoxicity Profiles of Selected KDM4 Inhibitors
cell line
cmpd fitting results LnCaP DU145 PC-3 HuPrEC
1 GI50 (μM)
a 410 >1000 >1000 >500




residualf 15% 69% 79% 12%
15 GI50 (μM) 8 8 >50 26
95% CI (μM) 7−9 7−10 NA 24−27
top 101% 101% 100 102
bottom 8% 4% NA 0%
hill slope −2.5 −1.8 NA −2.2
residual 1% 0% 27% 2%
ML324 GI50 (μM) 53 ND
h ND ND





aValues calculated from cell viability data using the log(inhibitor) vs
response−variable slope inhibition model in GraphPad Prism.
bFitting error reported as a 95% confidence interval. cHighest level
of cell viability fit as a variable in the inhibition model. dLowest level
of cell viability fit as a variable in the inhibition model. eSteepness, or
hill slope, of the dose-response curve. fPercentage of cell viability
remaining at the highest inhibitor concentration tested. gNot
applicable given a lack of growth inhibition at the concentration
range tested. hNot determined.
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Inhibition of AR-Dependent Gene Regulation in PCa
Cells. Given the measurable cytotoxicity exhibited by 15
against PCa model cell lines, we sought evidence that this
effect was directly mediated by the inhibition of intracellular
KDM activity. Since KDM4 enzymes stimulate gene
expression, we employed as the first measure, a luciferase-
based reporter assay to assess whether intracellular KDM
inhibition might also decrease the expression of a luciferase
reporter gene. The experimental strategy leveraged AR-
dependent gene expression, which can be stimulated in AR-
expressing cells, including the LnCaP PCa model cell line.28
This cell line responds to stimulation with AR ligands, in part
by increasing the expression of the clinical biomarker, prostate-
specific antigen (PSA). Accordingly, a luciferase-based reporter
assay was established by cloning the promoter and enhancer
regions of the human PSA gene upstream from the gene
encoding firefly luciferase and by transfecting the resulting
plasmid into LnCaP cells. Stimulation of transfected LnCaP
cells with the AR antagonist R1881 elicited a robust
luminescence signal from the reporter that was slightly,
although not significantly, augmented when cells were grown
in the presence of 0.5% (v/v) DMSO (Figure 5A). As a
positive control for intracellular KDM4 inhibition, cells were
treated with 50 μM of the cell-permeable inhibitor ML324. As
expected, treatment with ML324 caused a significant decrease
in luciferase expression, indicating that inhibition of intra-
cellular KDM4 activity reduces AR-dependent gene expression.
The effect was even more pronounced when cells were treated
with 25 μM of the optimized KDM4 inhibitor, compound 15
(Figure 5A), suggesting that this inhibitor mediates its
cytotoxic effects at least in part through inhibition of
intracellular KDMs.
Down-Regulation of Androgen-Receptor-Dependent
Gene Expression in PCa Cells. Given the relatively artificial
context of gene expression using a luciferase-based reporter
system, we performed qPCR-based experiments to further
assess, in a more native cellular context, whether treatment of
LnCaP cells with compound 15 affected AR-dependent PSA
gene expression. This technology has been successfully used in
the past to assess relative changes in PSA biomarker expression
in the LnCaP cell line.29 As a positive control, LnCaP cells,
grown in androgen-depleted media, were treated with the AR
agonist, dihydrotestosterone (DHT). As expected, this treat-
ment stimulated AR-mediated transcription of PSA (Figure
Figure 4. Cytotoxicity profiles of selected KDM4 inhibitors. Prostate-
derived cell lines were grown in the presence of KDM4 inhibitors, and
the resulting viabilities (reported above as percent cell viability) were
measured using the alamarBlue assay. (A) LnCaP cells were treated
with increasing concentrations of either compound 1 (green), ML324
(blue), or compound 15 (red). (B) An expanded panel of prostate
cancer cell lines was treated with compound 15 and assessed via the
alamarBlue assays as in panel A above. The following cancer cell lines
were compared: LnCaP (red), DU145 (blue), and PC3 (black).
Human prostate epithelial (HuPrEC) cells (green) were tested as a
healthy, non-malignant cell line control.
Figure 5. Compound 15 is active in cellular models of prostate
cancer. (A) Compound 15 inhibits gene expression in a luciferase-
based reporter gene assay. Relevant constituents present in each
experiment are indicated in the matrix above each bar. Statistical P
values from t-tests were calculated relative to the reporter signal
arising from untreated cells (for DMSO treatment, ns = not
significant; for ML324, *P = 0.0253; for compound 15, ***P <
0.0001). (B) Compound 15 inhibits endogenous expression of PSA in
AR+ LnCaP cells. Statistical P values were calculated relative to the
signal arising from PSA expression in cells treated with DMSO alone
(for ML324, **P = 0.0058; for compound 15, **P = 0.0078; for
compound 15 plus DHT, **P = 0.0021). (C) Chromatin extracted
from LnCaP cells treated with compound 15 exhibits significantly
higher levels of the H3K9me3 epigenetic mark compared to cells
treated with DMSO alone. Indicated at the top of panel C is a
representative western blot detecting the H3K9me3 epigenetic mark
(top bands) relative to static levels of a non-epigenetic epitope within
histone H4 (bottom bands). Relevant constituents present in each
experiment are indicated in the matrix above the blot. Depicted at the
bottom of panel C are the densitometric readings of the blot. Bar
heights measure mean signals from three biological replicates of either
untreated cells (white), DMSO-treated cells (black), or compound
15-treated cells (red). Statistical P values from t-tests were calculated
relative to the signal arising from untreated cells (for DMSO, ns = not
significant; for compound 15, *P = 0.0189). No significant differences
were measured in the H4 epitope. (D) Nucleosomal preparations
from LnCaP cells treated with membrane-permeable KDM4
inhibitors exhibit significantly higher levels of the H3K9me3
epigenetic mark (normalized to a static histone H4 epitope),
compared to treatment with DMSO alone. Statistical P values were
calculated relative either to the signal arising from cells grown under
basal conditions (for DMSO, ns = not significant) or relative to the
signal arising from cells grown in the presence of DMSO (for ML324,
**P = 0.0080; for compound 15, ***P = 0.0007).
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5B). Conversely, treatment of cells with 25 μM of KDM4
inhibitor 15 caused a highly significant decrease in PSA
expression. Interestingly, this effect was diminished but still
significant when cells were cotreated with DHT and 15. By
contrast, a weaker effect was observed when cells were treated
with 100 μM KDM4 inhibitor ML324 or with DMSO alone.
Chromatin from PCa Cells Treated with Compound
15 Remains in a Silenced and Heterochromatic
Epigenetic State. Whether compound 15-mediated de-
creases in gene expression occurred alongside maintenance
of a transcriptionally silent heterochromatic state was assessed
as the third line of evidence for intracellular KDM4 inhibition.
To test this, two immunochemical techniques were employed,
involving detection of the H3K9me3 epigenetic state. First,
purified chromatin was examined from untreated LnCaP cells,
from cells treated with 0.5% (v/v) DMSO, and from cells
treated with 25 μM compound 15. No significant differences in
the H3K9me3 epigenetic mark were discernible by western
blot analysis between healthy cells and DMSO-treated cells
relative to a static non-epigenetic motif within histone H4 used
as a loading control. By contrast, treatment with 15 caused a
significant increase in H3K9me3 abundance as would be
expected if intracellular KDM enzymes were inhibited (Figure
5C).
To corroborate this, nucleosomal ELISA (nu-ELISA)
experiments were performed, described originally to evaluate
the effects of HDAC inhibitors on global levels of histone
acetylation.30 Our previous use of this method18 further
demonstrated its utility in examining global states of chromatin
methylation. We reported that the treatment of both LnCaP
and DU145 cells with either DMSO or the original HTS hit
(compound 1) did not alter chromatin methylation relative to
untreated cells. Conversely, treatment with the cell-permeable
KDM4 inhibitor, ML324, caused significant increases in
chromatin methylation, consistent with the maintenance of a
heterochromatin state. Extending from these previous
observations, treatment of LnCaP cells with 25 μM of the
improved KDM4 inhibitor, compound 15, like ML324, caused
significant increases in the amounts of the H3K9me3
epigenetic mark in histone H3 relative to static non-epigenetic
motifs within histone H4 (Figure 5D). Similar nu-ELISA
results were observed when the DU145 cell line was cultured
under identical treatment conditions as outlined above (Figure
S10). Taken together, data from chromatin western-blotting
experiments and Nu-ELISA analyses both indicated that PCa
cells treated with cell-permeable KDM4 inhibitors ML324 and
compound 15 exhibited significant increases in epigenetic
marks associated with heterochromatin.
■ DISCUSSION AND CONCLUSIONS
Here, we describe the efforts to optimize a small-molecule
benzimidazole pyrazole-based scaffold that was previously
identified as an inhibitor of KDM4 enzymes. In doing so, we
employed a strategy to alter the molecule’s properties from
knowledge built upon existing literature reports. This work
proceeded via several modifications to the original scaffold,
including the introduction of motifs capable of forming
hydrogen bonds with KDM4E active-site residues (analogous
to those made by α-KG) and introduction of motifs capable of
engaging active-site regions that interact with the tri-
methylated ε-amino group of the H3K9me3 sidechain.
Surprisingly, none of these rational design features afforded
gains in inhibitor potency. Despite this outcome, one
prominent theme emerged from the scaffold’s SAR profile
(Scheme 3) that nonpolar substitutions generally enhanced
potency. In particular, aromatic substitutions at the scaffold’s
R2 position (compound 15) resulted in the most potent
design, yielding an inhibitor with greater than 10-fold
improved potency relative to the original HTS hit.
Determining a mechanism of action for this inhibitor was
challenging. Kinetic analyses revealed that 15 is non-
competitive with respect to the peptide substrate, indicating
that binding sites for these two molecules do not overlap. This
corroborates the finding that substituted amine modifications,
unlike the methylated epsilon amino-terminus of the
H3K9me3 substrate, did not enhance potency. By contrast,
the uncompetitive profile with respect to α-KG was
unexpected and more difficult to interpret. On the one hand,
this result indicates that 15 does not compete with α-KG and,
accordingly, that the binding sites do not overlap. This
corroborates the finding that substitutions incorporating
carboxylate sidechains, akin to α-KG, did not enhance potency.
Ultimately, the crystal structures reported herein helped to
clarify and confirm a plausible mechanism of action.
Accordingly, these structures did not reveal inhibitors bound
within KDM4A/D active sites, where α-KG is known to bind.
Presumably, this means that inhibitor-binding sites do not
overlap with α-KG and, in agreement with kinetic analyses,
that the benzimidazole pyrazole inhibitors tested are therefore
not competitive with respect to this cosubstrate. Data from
KDM4D crystals soaked with compound 1 were more
definitive. These data indicated that a primary determinant
of inhibition for the benzimidazole pyrazole-based inhibitors is
Scheme 3. Schematic Overview of the Investigated Structure−Activity Relationshipa
aRegions highlighted in red constitute an essential structural framework for binding activity.
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the removal of active-site iron. Chelation of iron was expected
given the scaffold’s bidentate chelation center comprising two
nitrogen atoms. The metal-binding site found in the inhibitor
scaffold therefore likely competes with the enzyme for Fe2+
binding, thereby inhibiting its activity.
The KDM4A structures also demonstrated that the
inhibitors are capable of binding to a distal site comprising a
small hydrophobic binding pocket on the catalytic domain’s
surface. From a SAR perspective, these structures reconcile the
observation that inhibitor potency increased upon introduction
of nonpolar substitutions into the scaffold’s R2 position and
decreased upon introduction of polar substitutions. Further-
more, the observation that potency decreased upon extension
of the benzylpyrazole linker or upon introducing a tolyl
substitution corroborates preference of a phenyl function at
position R2, likely reflecting binding to this shallow hydro-
phobic pocket on KDM4 enzyme surfaces. Extending from
this, modifications that increase affinity for this distal binding
site may enhance competition for active-site metal by
incorporating an alternative binding site that would otherwise
not exist. This mode of binding also demonstrates why gains in
potency were not observed upon substitution of the inhibitor’s
benzimidazole ring or upon exchange of the benzimidazole
moiety to a pyridine or to a pyridazine.
This distal binding site is structurally conserved amongst
catalytic domains of all members of the KDM4 superfamily
and, to date, has not yet been described as a site capable of
inhibiting JmjC-KDM enzymes. Aside from the aforemen-
tioned possibility of enhancing competition for active-site Fe2+,
further means by which binding to this site affects KDM4
activity remain speculative. Comparisons between the KDM4A
structures presented here and those of other KDM4A catalytic
domains22,24,31,32 indicate no obvious conformational changes
that propagate to the active site upon binding of the molecules
described here. However, binding of the inhibitor to this site
could prevent subtle molecular motion required by the enzyme
for substrate turnover.
There is at least some structural evidence suggesting that the
distal surface binding site is generally accessible to binding
since several JmjC-KDM4 structures have been published
depicting cryoprotectant molecules bound there. Relevant
examples include, but are not limited to, structures of the
isoforms KDM4A33 (PDB ID 5F3C), KDM4C (PDB ID
5FJK), and KDM4D34 (PDB ID 5PHA) with cryoprotectant
molecules forming hydrogen bonds to the homologous Thr
residue that interacts with compounds 26 and 30, as observed
in the KDM4A structures presented here. Given the frequency
at which interactions are seen at this surface on these isoforms,
it may represent an interaction hotspot, targetable, for example,
by molecules derived from fragment-like compound libraries.
Extending from this, the structural conservation amongst
members of the KDM4 family noted above would also suggest
that the benzimidazole pyrazole scaffold is not likely to be
selective for any particular KDM4 isoform.
Another intriguing outcome arising from the distal binding
site follows that binding to this site might contribute to the
biphasic inhibition curves that we previously reported. In
addition to the clear and most obvious outcome that the
investigated benzimidazole pyrazole inhibitors inhibit KDM4
enzymes, at least partially (or mainly) via removal of active-site
Fe2+, it is possible that binding to this surface site mediates a
secondary inhibitory effect, manifesting in some dose−
response curves as biphasic inhibition. In such a model, one
inhibitory phase might correspond to an event described by
chelation of the active-site metal, with the second inhibitory
phase corresponding to an event described by binding to the
distal hydrophobic pocket.
The second goal of our optimization campaign was largely
successful with regard to the activity of the KDM4 inhibitors in
cellular models of prostate cancer. First, marked improvements
to cellular penetrance were observed upon introduction of the
benzyl substitution of compound 15, especially relative to the
original HTS hit, compound 1, which had only marginal
antiproliferative activity. This outcome facilitated the assess-
ment of whether the cellular uptake of 15 affected KDM4-
dependent processes. Using the KDM4+ and AR+ LnCaP cell
line as a model of PCa, the results presented here
demonstrated that this was indeed the case. First, by the use
of a reporter gene assay, intracellular 15 was demonstrated to
inhibit the expression of the firefly luciferase gene under the
control of an AR promoter. Since this reporter system may not
directly reproduce the endogenous chromatin environment in
which KDM4 enzymes are active, a second strategy was
employed to directly measure AR-dependent gene expression.
Accordingly, these qPCR-based analyses demonstrated that,
along with the known cell-permeable KDM4 inhibitor ML324,
compound 15 was also able to repress the AR-dependent
expression of PSA. Furthermore, by directly measuring the
epigenetic states of chromatin purified from LnCaP and
DU145 cells, we demonstrated that cells treated with
compound 15 (or with ML324) exhibited significantly lower
amounts of the H3K9me3 epigenetic mark relative to
untreated cells or relative to cells treated with DMSO alone.
Collectively, these experiments provide strong evidence that 15
inhibits KDM4 activity in cell lines known to express these
targets.
Together with the results from the biochemical assays
presented here, we consider that 15 can directly interact with
KDM4 targets in living cells. However, we also acknowledge
that scavenging of active-site Fe2+ may underscore a primary
inhibitory role in such cells, especially since the biochemical
assays involved isolated catalytic domains of these enzymes,
outside the context of both their additional reader domains
and outside of the greater nucleosomal environment in which
they operate. As technologies for assessing cellular target
engagement become more refined, they will almost certainly be
of benefit to prove whether direct interactions occur. If so, we
believe that the improved properties of compound 15 can be
leveraged and further engineered to increase potency and
engagement with KDM4 targets.
In conclusion, the work presented here demonstrated
marked improvements to a benzimidazole pyrazole scaffold.
A benzylpyrazole-substituted variant yielded the most potent
KDM4 inhibitor tested, inhibiting the enzyme in part by active-
site metal removal and possibly via binding to a distal binding
pocket. Unlike the parent molecule, compound 15 is active in
cellular models of PCa where it decreases both AR-dependent
gene expression and the removal of H3K9me3 epigenetic
marks presumably by KDM4 inhibition. We believe these
favorable properties of compound 15 merit its consideration
either clinically as an anti-cancer agent or as a molecular probe
to investigate the effects of KDM4 inhibition in relevant
cellular models.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c00693
J. Med. Chem. 2021, 64, 14266−14282
14275
■ EXPERIMENTAL SECTION
Chemicals and Reagents. Chemicals and synthesis reagents
were purchased from Sigma-Aldrich (St. Louis, MO). KDM4
inhibitors ML324 and 2,4-PDCA were from Active Motif (Carlsbad,
CA) and Sigma-Aldrich (St. Louis, MO), respectively. Selected
pyrazole and benzimidazole scaffolds were purchased from MolPort
SIA (Riga, LV). Purchased compounds were used without further
purification. Enzymology reagents (α-KG), sodium ascorbate, Fe-
(NH4)2(SO4)2, NAD
+, and TMB (ELISA substrate) were purchased
from Sigma-Aldrich (St. Louis, MO). Antibodies were purchased from
Thermo Fisher Scientific (Waltham, MA) (rabbit pAb H3K9me3,
Invitrogen #49-1008), Abcam (Cambridge, UK) (mouse mAb
H3K9me3, #ab6001), BioVision (Milpitas, CA) (rabbit pAb histone
H4, #3624-100), and Cell Signaling Technology (Danvers, MA)
(HRP-mouse anti-rabbit IgG, #7074 or HRP-rabbit anti-mouse IgG,
#7076).
Small-Molecule Synthesis. Reagents and solvents were obtained
from commercial suppliers and used without further purification.
Organic solvents were dried using molecular sieves. 1H NMR and 13C
NMR spectra were recorded either on an AV 300 MHz or on an AV
600 MHz from Bruker. Chemical shifts were recorded in parts per
million (ppm). Spin multiplicities are described as s (singlet), d
(doublet), t (triplet), q (quartet), or m (multiplet). Coupling
constants (J) were recorded in Hz. NMR data were analyzed with
MestReNova software. Mass analyses were performed with two
different spectrometers using the same column, as described below.
Purity and characterization of all final compounds were established by
a combination of LC−MS, LC-HRMS, and NMR analytical
techniques. All compounds were found to be >95% pure by LC−
MS and LC-HRMS analysis unless otherwise stated.
LCMS (method 1): Instrument: Agilent Technologies 6220
Accurate Mass TOF LC/MS linked to Agilent Technologies HPLC
1260 Series; Column: Thermo Accuore RP-MS; particle size: 2.6 μM,
dimension: 30 × 2.1 mm; eluent A: H2O with 0.1% formic acid;
eluent B: MeCN with 0.1% formic acid; conditions: 0.00 min 95% A,
0.2 min 95% A, 2.1 min to 1% A as gradient, 3 min as stop time, 1.3
min post time for reconstitution; flow rate: 0.8 mL/min; UV-
detection: 220, 254, 300 nm.
LCMS (method 2): Instrument: Agilent Technologies 6120
Quadrupole LC/MS linked to Agilent Technologies HPLC 1290
Infinity; Column: Thermo Accuore RP-MS; particle size: 2.6 μM,
dimension: 30 × 2.1 mm; eluent A: H2O with 0.1% TFA; eluent B:
MeCN with 0.1% TFA; gradient: 0.00 min 95% A, 0.2 min 95% A, 1.1
min to 1% A as gradient, 2.5 min as stop time, 1.3 min post time for
reconstitution; Flow rate: 0.8 mL/min; UV-detection: 220, 254, and
300 nm. Purification of the compounds by chromatography was
achieved using a CombiFlash Rf 200 UV-VIS System from Axel
Semrau.
Preparative HPLC method: Instrument: Waters Prep 150 LC
System ChromScope v. 1.4; Column: Machery-Nagel VP 250 × 21
mm Nucleodur 100-7 C18; eluent A: H2O with 0.1% TFA; eluent B:
MeCN with 0.1% TFA; gradient: 0.00 min 85% A, 2 min 85% A, 22
min 15% A, 24 min 15% A, 26 min 0% A, 29 min 0% A, 32 min 85%
A; Flow rate: 30 mL/min; UV-detection: 254 nm.
Compound 1: Methyl 2-(1-(1H-benzo[d]imidazol-2-yl)-5-hy-
droxy-1H-pyrazol-3-yl)acetate. 50 mg of (0.34 mmol) (1H-1,3-
benzimidazol-2-yl)hydrazine was solubilized in 1.5 mL of MeOH. 58
mg of (0.34 mmol) dimethyl 3-oxopentanedioate was added, and the
mixture was heated to 45 °C. After 2 h, MeOH was removed under
reduced pressure and the crude product was solubilized in 2 mL of
(ACN/H2O). The product was purified by HPLC, eluting in a
gradient of ACN/H2O (yield: 16.2 mg, 17%).
1H NMR (300 MHz,
DMSO-d6): δ 7.51 (dd, J = 6.0, 3.2 Hz, 2H), 7.16 (dd, J = 6.0, 3.2 Hz,
2H), 5.24 (s, 1H), 3.64 (s, 3H), and 3.59 (s, 2H). 13C NMR (75
MHz, DMOS-d6): δ 170.4, 150.1, 145.4, 135.8, 122.3, 114.5, 52.1, and
34.9. LCMS (method 1): Rt = 1.051 min; HRMS (ESIpos): m/z [M
+ Na]+ calcd for C13H12N4O3, 295.0802; found, 295.0799.
Compound 2: 2-(1-(1H-Benzo[d]imidazol-2-yl)-5-hydroxy-1H-
pyrazol-3-yl)acetic Acid. 16 mg of (0.33 mmol) 1 was dissolved in
1 mL of THF, and 1 mL of 1 M LiOH aqueous solution was added.
After saponification, the mixture was acidified with 2 M HCl to pH <
3 and the product, precipitated as a white solid, was filtered off, and
washed with water and with Et2O (yield: 15 mg, quant).
1H NMR
(300 MHz, DMSO-d6): δ 7.49−7.37 (m, 2H), 7.05−6.95 (m, 2H),
4.59 (s, 1H), and 3.17 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ
175.0, 165.8, 153.5, 149.1, 120.7, 83.4, and 48.9, CH2CO2H overlay
DMSO peak. LCMS (method 1): Rt = 0.883 min; HRMS (ESIpos):
m/z [M + Na]+ calcd for C12H10N4O3, 259.0826; found, 259.0828.
Compound 3: Methyl 3-(1-(1H-benzo[d]imidazol-2-yl)-5-hy-
droxy-3-methyl-1H-pyrazol-4-yl)propanoate. 22 mg of (0.15
mmol) (1H-1,3-benzimidazol-2-yl)hydrazine was solubilized in 0.5
mL of MeOH. 30 mg of (0.15 mmol) dimethyl 2-acetylglutarate was
added, and the mixture was heated to 45 °C. After 2 h, MeOH was
removed under reduced pressure, 1 mL of Et2O was added, and the
product, precipitated as a white solid, was filtered off and washed with
Et2O (yield: 34 mg, 76%).
1H NMR (300 MHz, chloroform-d): δ
7.44−7.37 (m, 2H), 7.26−7.21 (m, 2H), 3.70 (s, 3H), 2.73−2.70 (m,
4H), and 2.24 (s, 3H). LCMS (method 2): Rt = 0.948 min; MS
(ESIpos): m/z [M + H]+ 301.2.
Compound 4: Ethyl 3-(1-(1H-benzo[d]imidazol-2-yl)-5-hydroxy-
4-methyl-1H-pyrazol-3-yl)propanoate. 20 mg of (0.14 mmol) (1H-
1,3-benzimidazol-2-yl)hydrazine was solubilized in 1 mL of EtOH. 30
mg of (0.14 mmol) diethyl-2-methyl-3-oxoadipate was added, and the
mixture was heated to 75 °C. After 2 h, EtOH was removed under
reduced pressure, 1 mL of Et2O was added, and the product,
precipitated as a white solid, was filtered off and washed with Et2O
(yield: 20 mg, 51%). 1H NMR (300 MHz, chloroform-d): δ 7.60−
7.52 (m, 2H), 7.36−7.30 (m, 2H), 4.15 (q, J = 7.2 Hz, 2H), 2.92 (t, J
= 7.2 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 1.95 (s, 3H), and 1.25 (t, J =
7.1 Hz, 3H). LCMS (method 2): Rt = 1.029 min; MS (ESIpos): m/z
[M + H]+ 315.2.
Compound 5: 3-(1-(1H-Benzo[d]imidazol-2-yl)-5-hydroxy-3-
methyl-1H-pyrazol-4-yl)propanoic Acid. 20 mg of (0.07 mmol) 3
was dissolved in 1 mL of THF, and 1 mL of 1 M LiOH aqueous
solution was added. After saponification, the mixture was acidified
with 2 M HCl to make the pH = 3, and the product, precipitated as a
white solid, was filtered off and washed with water and with Et2O
(yield: 19 mg, quant). 1H NMR (300 MHz, DMSO-d6): δ 7.62−7.55
(m, 2H), 7.30−7.24 (m, 2H), 2.56−2.44 (m, 4H, overlay DMSO),
and 2.22 (s, 3H). LCMS (method 2): Rt = 0.864 min; MS (ESIpos):
m/z [M + H]+ 281.1.
Compound 6: 3-(1-(1H-benzo[d]imidazol-2-yl)-5-hydroxy-4-
methyl-1H-pyrazol-3-yl)propanoic Acid. 10 mg of (0.035 mmol) 4
was dissolved in 1 mL of THF and 1 mL of 1 M LiOH aqueous
solution was added. After saponification, the mixture was acidified
with 2 M HCl to pH < 3, and the product, precipitated as a white
solid, was filtered off and washed with water and with Et2O (yield: 9
mg, quant). 1H NMR (300 MHz, DMSO-d6): δ 7.56−7.48 (m, 2H),
7.19−7.13 (m, 2H), 2.77 (t, J = 7.9 Hz, 2H), 2.62 (t, J = 7.4 Hz, 2H),
and 1.80 (s, 3H). LCMS (method 2): Rt = 0.88 min; MS (ESIpos):
m/z [M + H]+ 287.2.
Compound 7: 3-(1-(1H-Benzo[d]imidazol-2-yl)-5-hydroxy-3-
methyl-1H-pyrazol-4-yl)-N-methylpropanamide. 114 mg of (0.4
mmol) 5 was dissolved in 1 mL of DMF, and 54.2 mg of (0.4 mmol)
HOBt, 76.3 mg of (0.4 mmol) EDC, and 138 μL (0.8 mmol) of
DIPEA were added to the reaction mixture. 34 μL of (0.4 mmol)
methylamine was added, and the mixture was stirred for 16 h. After
completion of the amidation, the mixture was quenched with H2O
and extracted 3 times with DCM. The combined organic phases were
removed under reduced pressure, and the raw product was purified by
HPLC, eluting in a gradient of ACN/H2O (yield: 67 mg, 56%).
1H
NMR (300 MHz, DMSO-d6): δ 7.94−7.85 (m, 1H), 7.59−7.54 (m,
2H), 7.26−7.20 (m, 2H), 2.57 (s, 3H), 2.52−2.46 (m, 2H, overlay
DMSO peak), 2.30 (t, J = 7.4 Hz, 2H), and 2.18 (s, 3H). 13C NMR
(75 MHz, DMSO-d6): δ 172.6, 158.9, 152.3, 143.2, 134.8, 122.9,
114.5, 102.4, 35.0, 25.9, 18.0, and 11.9. LCMS (method 1): Rt = 1.145
min; HRMS (ESIpos): m/z [M + H]+ calcd for C15H17N5O2,
300.1455; found, 300.1455.
Compound 8: 3-(1-(1H-Benzo[d]imidazol-2-yl)-5-hydroxy-3-
methyl-1H-pyrazol-4-yl)-N,N-dimethylpropanamide. 114 mg of
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(0.4 mmol) 6 was dissolved in 1 mL of DMF, and 54.2 mg of (0.4
mmol) HOBt, 76.3 mg of (0.4 mmol) EDC, and 138 μL (0.8 mmol)
of DIPEA were added to the reaction mixture. 200 μL of (0.4 mmol 2
M in THF) dimethylamine was added, and the mixture was stirred for
16 h. After completion of the amidation, the mixture was quenched
with H2O and extracted 3 times with DCM. The combined organic
phases were removed under reduced pressure, and the raw product
was purified by HPLC, eluting in a gradient of ACN/H2O (yield: 58
mg, 47%). 1H NMR (300 MHz, DMSO-d6): δ 7.57−7.50 (m, 2H),
7.23−7.17 (m, 2H), 2.95 (s, 3H), 2.82 (s, 3H), 2.57−2.45 (m, 4H,
overlay DMSO peak), and 2.20 (s, 3H). 13C NMR (75 MHz, DMSO-
d6): δ 172.0, 158.9, 151.6, 143.4, 135.5, 122.6, 114.6, 102.5, 37.0, 35.2,
32.1, 17.7, and 11.7. LCMS (method 1): Rt = 1.248 min; HRMS
(ESIpos): m/z [M + H]+ calcd for C16H19N5O2, 314.1612; found,
314.1612.
Compound 9: 1-(1H-Benzo[d]imidazol-2-yl)-3-methyl-4-(3-
(methylamino)propyl)-1H-pyrazol-5-ol. 30 mg of (0.1 mmol) 7
was dissolved in 1 mL of DCM/THF 1:1, and 24 μL of borane
dimethylsulfide complex (δ = 0.801 g/mL, 0.25 mmol) was added.
The reaction was quenched with H2O, and NaOH was added to make
the pH = 10. The aqueous phase was extracted 3 times with Et2O.
The combined organic phases were removed under reduced pressure,
and the raw product was purified by HPLC, eluting in a gradient of
ACN/H2O (yield: 8 mg, 28%).
1H NMR (300 MHz, DMSO-d6): δ
8.84 (s, 2H), 7.57−7.48 (m, 2H), 7.19−7.12 (m, 2H), 2.96−2.85 (m,
2H), 2.52−2.48 (m, 2H), 2.31 (t, J = 7.1 Hz, 2H), 2.19 (s, 3H), and
1.84−1.74 (m, 2H). LCMS (method 2): Rt = 0.44 min; MS (ESIpos):
m/z [M + H]+ 286.2.
Compound 10 : 1 - (1H-Benzo[d] imidazo l -2-y l ) -4- (3-
(dimethylamino)propyl)-3-methyl-1H-pyrazol-5-ol. 30 mg of (0.1
mmol) 8 was dissolved in 1 mL of DCM/THF 1:1, and 24 μL of
borane dimethylsulfide complex (δ = 0.801 g/mL, 0.25 mmol) was
added. The reaction was quenched with H2O, and NaOH was added
to make the pH = 10. The aqueous phase was extracted 3 times with
Et2O. The combined organic phases were removed under reduced
pressure, and the raw product was purified by HPLC, eluting in a
gradient of ACN/H2O (yield: 7 mg, 24%).
1H NMR (300 MHz,
DMSO-d6): δ 7.55−7.48 (m, 2H), 7.17−7.12 (m, 2H), 2.74−2.68
(m, 2H), 2.46 (s, 6H), 2.24 (t, J = 7.3 Hz, 2H), 2.18 (s, 3H), and
1.91−1.80 (m, 2H). LCMS (method 2): Rt = 1.006 min; MS
(ESIpos): m/z [M + H]+ 300.3.
Compound 11: 1-(1H-Benzo[d]imidazol-2-yl)-3-methyl-1H-pyr-
azol-5-ol. 19 mg of (0.13 mmol) (1H-1,3-benzimidazol-2-yl)-
hydrazine was solubilized in 0.5 mL of MeOH. 20 mg of (0.13
mmol) methyl acetoacetate was added, and the mixture was heated to
45 °C. After cooling to RT, a white solid precipitated as a side
product. The mixture was centrifuged and the filtrate contained the
pure product. The white solid was washed with MeOH several times,
followed by centrifugation. The combined organic MeOH phases
were removed under reduced pressure, and the product was obtained
as a white solid (yield: 19 mg, 67%). 1H NMR (300 MHz, DMSO-
d6): δ 7.55−7.49 (m, 2H), 7.18−7.13 (m, 2H), 5.23 (s, 1H), and 2.19
(s, 3H). 13C NMR (75 MHz, DMSO-d6): δ 161.4, 153.0, 144.2,
136.4, 122.2, 114.7, 90.2, and 13.3. LCMS (method 1): Rt = 0.798
min; HRMS (ESIpos): m/z [M + H]+ calcd for C11H10N4O,
215.0927; found, 215.0927.
Compound 12: 4-Allyl-1-(1H-benzo[d]imidazol-2-yl)-3-methyl-
1H-pyrazol-5-ol. 43.5 mg of (0.29 mmol) (1H-1,3-benzimidazol-2-
yl)hydrazine was solubilized in 4 mL of EtOH. 50 mg of (0.29 mmol)
ethyl-2-acetylpent-4-enoate was added, and the mixture was heated to
80 °C. After 2 h, EtOH was removed under reduced pressure, and the
crude product was solubilized in 2 mL of (ACN/H2O). The product
was purified by HPLC, eluting in a gradient of ACN/H2O (yield: 14
mg, 19%). 1H NMR (300 MHz, chloroform-d): δ 9.52 (s, 2H), 7.69−
7.59 (m, 2H), 7.47−7.39 (m, 2H), 5.95−5.80 (m, 1H), 5.11 (dd, J =
1.9 Hz, 1H), 5.07 (dd, J = 4.1, 1.9 Hz, 1H), 3.12 (dt, J = 6.1, 1.8 Hz,
2H), and 2.32 (s, 3H). 13C NMR (75 MHz, chloroform-d): δ 164.6,
164.2, 156.4, 141.5, 134.4, 115.6, 102.4, 25.5, and 11.7. LCMS
(method 1): Rt = 1.223 min; HRMS (ESIpos): m/z [M + H]
+ calcd
for C14H14N4O, 255.1240; found, 255.1246.
Compound 13: 1-(1H-Benzo[d]imidazol-2-yl)-3-methyl-4-prop-
yl-1H-pyrazol-5-ol. 12 mg of (0.05 mmol) 12 was dissolved in 1 mL
of MeOH, and Pd/C was added. The reaction vessel was flushed with
hydrogen and stirred for 1 h at RT. Pd/C was filtered off with celite,
and the solvent was removed under reduced pressure. The product
was purified by HPLC, eluting in a gradient of ACN/H2O (yield: 10.9
mg, 90%). 1H NMR (300 MHz, methanol-d4): δ 7.68−7.60 (m, 2H),
7.45−7.36 (m, 2H), 2.41−2.32 (m, 2H), 2.32−2.25 (m, 3H), 1.64−
1.52 (m, 2H), and 1.03−0.93 (m, 3H). 13C NMR (75 MHz,
methanol-d4): δ 159.0, 155.3, 141.9, 131.7, 124.0, 113.2, 104.3, 23.0,
22.2, 12.6, and 10.9. LCMS (method 1): Rt = 1.306 min; HRMS
(ESIpos): m/z [M + H]+ calcd for C14H16N4O, 257.1397; found,
257.1396.
Compound 14: 1-(1H-Benzo[d]imidazol-2-yl)-3-methyl-4-(prop-
2-yn-1-yl)-1H-pyrazol-5-ol. 81 mg of (0.55 mmol) (1H-1,3-
benzimidazol-2-yl)hydrazine was solubilized in 2 mL of EtOH. 92
mg of (0.55 mmol) ethyl 2-acetylpent-4-ynoate was added, and the
mixture was heated to 75 °C. After 2 h, EtOH was removed under
reduced pressure, and the raw product was purified by HPLC, eluting
in a gradient of ACN/H2O (yield: 54 mg, 39%).
1H NMR (300 MHz,
DMSO-d6): δ 7.55 (dd, J = 5.8, 3.1 Hz, 2H), 7.22 (dd, J = 5.8, 3.1 Hz,
2H), 3.25−3.18 (m, 2H), 2.84 (t, J = 2.9 Hz, 1H), and 2.25 (s, 3H).
13C NMR (75 MHz, DMSO-d6): δ 159.4, 151.8, 143.4, 135.3, 122.7,
114.6, 97.6, 82.3, 70.9, 11.9, and 11.2. LCMS (method 1): Rt = 1.179
min; HRMS (ESIpos): m/z [M + H]+ calcd for C14H13N4O,
253.1084; found, 253.1082.
Compound 15: 1-(1H-Benzo[d]imidazol-2-yl)-3-methyl-4-phe-
nyl-1H-pyrazol-5-ol. 1.05 g (0.01 mol) of (1H-1,3-benzimidazol-2-
yl)hydrazine was solubilized in 40 mL of EtOH. 1.46 g (0.01 mol) of
ethyl 3-oxo-2-phenylbutanoate was added, and the reaction mixture
was stirred at 80 °C for 16 h. EtOH was evaporated, and the crude
product was purified by chromatography on silica gel, eluting with a
gradient of DCM/MeOH (yield: 640 mg 31%). 1H NMR (300 MHz,
DMSO-d6): δ 7.66 (d, J = 7.6 Hz, 2H), 7.60−7.53 (m, 2H), 7.41−
7.33 (m, 2H), 7.23 (dd, = 6.0, 3.2 Hz, 2H), 7.19−7.13 (m, 1H), and
2.40 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ 160.9, 151.1, 143.5,
134.6, 133.4, 128.5, 127.0, 125.1, 122.8, 114.4, 100.6, and 14.2. LCMS
(method 1): Rt = 1.305 min; HRMS (ESIpos): m/z [M + H]
+ calcd
for C17H14N4O, 291.1240; found, 291.1238.
Compound 16: 1-(1H-Benzo[d]imidazol-2-yl)-4-benzyl-3-meth-
yl-1H-pyrazol-5-ol. 33.6 mg of (0.23 mmol) (1H-1,3-benzimidazol-2-
yl)hydrazine was solubilized in 4 mL of EtOH. After addition of 50
mg of (0.23 mmol) ethyl-2-benzylacetoacetate, the reaction mixture
was stirred at 80 °C for 2 h. EtOH was evaporated, solubilized in
ACN/H2O, and purified by HPLC, eluting in a gradient of ACN/
H2O (yield: 29 mg, 42%).
1H NMR (300 MHz, chloroform-d): δ 9.29
(s, 2H), 7.61−7.53 (m, 2H), 7.42−7.34 (m, 2H), 7.30−7.17 (m, 5H),
3.70 (s, 2H), and 2.28 (s, 3H). 13C NMR (75 MHz, chloroform-d): δ
164.7, 156.1, 141.4, 138.9, 128.5, 127.9, 126.4, 125.1, 104.0, 27.4, and
11.9. LCMS (method 1): Rt = 1.329 min; HRMS (ESIpos): m/z [M
+ H]+ calcd for C18H16N4O, 305.1397; found, 305.1383.
Compound 17: 1-(1H-Benzo[d]imidazol-2-yl)-3-methyl-4-(p-
tolyl)-1H-pyrazol-5-ol. 40 mg of (0.27 mmol) (1H-1,3-benzimida-
zol-2-yl)hydrazine was solubilized in 4 mL of EtOH. 60 mg of (0.27
mmol) ethyl 3-oxo-2-p-tolylbutanoate was added, and the reaction
mixture was stirred at 80 °C for 2 h. EtOH was evaporated, and the
crude product was homogenized in 1 mL of MeOH. Upon addition of
H2O, the product precipitated and was filtered off and washed with
ether (yield: 39 mg, 47%). 1H NMR (300 MHz, DMSO-d6): δ 7.59−
7.50 (m, 4H), 7.22−7.12 (m, 4H), 2.36 (s, 3H), and 2.29 (s, 3H). 13C
NMR (75 MHz, DMSO-d6): δ 161.0, 150.3, 144.6, 135.6, 133.8,
130.8, 129.1, 126.9, 122.3, 114.4, 100.4, 21.1, and 14.4. LCMS
(method 1): Rt = 1.365 min; HRMS (ESIpos): m/z [M + H]
+ calcd
for C18H16N4O, 305.1397; found, 305.1398.
Compound 18: 1-(1H-Benzo[d]imidazol-2-yl)-3-ethyl-4-phenyl-
1H-pyrazol-5-ol in Three Steps. Synthesis of methyl 3-hydroxy-2-
phenylpentanoate: 187 μL of (1.33 mmol) methyl phenylacetate was
dissolved in 5 mL of THF. The reaction mixture was cooled to −78
°C, and LDA was added, followed by the addition of 96 μL of (1.33
mmol) propionaldehyde solubilized in 3 mL of THF. The mixture
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was kept for 1 h at −78 °C and then allowed to warm to 0 °C and
quenched with an NH4Cl solution. The aqueous phase was washed 3
times with EtOAc and dried over Mg2SO4. The crude product was
purified by chromatography on silica gel, eluting with a gradient of
hexane/EtOAc. Fractions containing the product were combined, and
the solvent was evaporated under reduced pressure (yield: 46.5 mg,
17%). 1H NMR (300 MHz, chloroform-d): δ 7.37−7.26 (m, 5H),
4.12 (td, J = 8.7, 3.4 Hz, 1H), 3.69 (s, 3H), 3.61 (d, J = 9.2 Hz, 1H),
1.33, 1.22 (m, 2H), and 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz,
chloroform-d): δ 174.1, 136.1, 128.7, 128.3, 127.6, 74.4, 58.1, 52.1,
26.6, and 9.6. LCMS (method 1): Rt = 1.328 min; HRMS (ESIpos):
m/z [M + Na]+ calcd for C12H16O3, 231.0992; found, 231.0986.
To 2 mL of DCM solution at −78 °C, 63 μL of (0.89 mmol)
DMSO and 70 μL of (0.67 mmol) oxalyl chloride were added, and
the mixture was stirred for 10 min. Afterward, 46.5 mg of (0.22
mmol) of methyl 3-hydroxy-2-phenylpentanoate, together with 370
μL of (2.9 mmol) of trimethylamine in 900 μL of DCM were added
dropwise at −78 °C. After 2 h, the mixture was quenched with 2 M
HCl, and the aqueous phase was extracted 3 times with DCM. The
combined organic phases were dried with Na2SO4, DCM was
removed under reduced pressure, and the raw product was obtained
as a yellowish oil (70 mg). It was used as the raw product in the last
step of the synthesis. 33 mg of (0.22 mmol) (1H-1,3-benzimidazol-2-
yl)hydrazine was solubilized in 1 mL of EtOH. After the addition of
raw 70 mg of (0.55 mmol) methyl 3-oxo-2-phenylpentanoate, the
reaction mixture was stirred at 75 °C for 2 h. EtOH was evaporated,
and the crude product was solubilized in ACN/H2O and purified by
HPLC, eluting in a gradient of ACN/H2O (yield: 8 mg, 12% for two
steps). 1H NMR (300 MHz, chloroform-d): δ 7.53 (d, J = 7.2 Hz,
3H), 7.49−7.41 (m, 3H), 7.39−7.31 (m, 3H), 2.87 (q, J = 7.6 Hz,
2H), and 1.33 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, chloroform-
d): δ 164.4, 163.0, 160.0, 141.7, 129.7, 128.7, 128.6, 127.3, 125.0,
105.3, 20.3, and 12.4. LCMS (method 1): Rt = 1.376 min; HRMS
(ESIpos): m/z [M + H]+ calcd for C18H16N4O, 305.1397; found,
305.1399.
Compound 19: 1-(1H-Benzo[d]imidazol-2-yl)-3-butyl-4-phenyl-
1H-pyrazol-5-ol in Three Steps. Synthesis of methyl 3-hydroxy-2-
phenylheptanoate: 187 μL of (1.33 mmol) of methyl phenylacetate
was dissolved in 5 mL THF. The reaction mixture was cooled to −78
°C, and 107 μL of 1 M LDA solution in THF (2 mmol) was added.
The mixture was stirred at −78 °C for 30 min, followed by the
addition of 141 μL of (1.33 mmol) valeraldehyde. The crude product
was quenched at 0 °C with an NH4Cl solution, and the aqueous phase
was washed 3 times with EtOAc and dried over Mg2SO4. The product
was purified by chromatography on silica gel, eluting with a gradient
of hexane/EtOAc. Fractions containing the product were combined,
and the solvent was evaporated under reduced pressure (yield: 42 mg,
13%). 1H NMR (300 MHz, chloroform-d): δ 7.42−7.28 (m, 43H),
4.24−4.17 (m, 1H), 3.69 (s, 3H), 3.60 (d, J = 6.3 Hz, 1H), 2.42 (s,
1H), 1.42−1.26 (m, 6H), and 0.90 (t, J = 7.1 Hz, 4H). 13C NMR (75
MHz, chloroform-d): δ 173.7, 135.0, 129.1, 128.6, 127.7, 72.1, 57.1,
52.0, 34.1, 27.8, 22.5, and 13.9. LCMS (method 1): Rt = 1.328 min;
HRMS (ESIpos): m/z [M + Na]+ calcd for C12H16O3, 231.0992;
found, 231.0986.
To 2 mL of a DCM solution at −78 °C, 50 μL of (0.71 mmol) of
DMSO and 52 μL of (0.53 mmol) of oxalyl chloride were added, and
the mixture was stirred for 10 min. Afterward, 42 mg of (0.18 mmol)
of methyl 3-hydroxy-2-phenylheptanoate together with 294 μL of (2.1
mmol) of trimethylamine in 700 μL of DCM were added dropwise at
−78 °C. After 2 h, the mixture was quenched with 2 M HCl, and the
aqueous phase was extracted 3 times with DCM. The combined
organic phases were dried with Na2SO4, DCM was removed under
reduced pressure, and the raw product was obtained as a yellowish oil
(42 mg). It was used as the raw product in the last step of the
synthesis. 27 mg of (0.18 mmol) (1H-1,3-benzimidazol-2-yl)-
hydrazine was solubilized in 1 mL of EtOH. After the addition of
42 mg of (0.18 mmol) methyl 3-oxo-2-phenylheptanoate, the reaction
mixture was stirred at 75 °C for 2 h. EtOH was evaporated, and the
crude product was solubilized in ACN/H2O and purified by HPLC,
eluting in a gradient of ACN/H2O (yield: 13 mg, 23% for two steps).
1H NMR (300 MHz, chloroform-d): δ 7.51 (t, J = 6.4 Hz, 3H), 7.47−
7.32 (m, 5H), 2.84 (t, J = 1901.2, 0.0 Hz, 3H), 1.78−1.66 (m, 2H),
1.48−1.36 (m, 2H), and 0.92 (t, J = 7.3 Hz, 3H). LCMS (method 2):
Rt = 1.221 min; MS (ESIpos): m/z [M + H]
+ 333.2.
Compound 20: 2-(4-Bromo-1H-pyrazol-1-yl)-1H-benzo[d]-
imidazole in Two Steps. 88 mg of (0.24 mmol) 2-bromo-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole was dissolved
in 0.5 mL of DMF. 232 mg of (0.71 mmol) Cs2CO3 and 50 mg of
(0.24 mmol) 4-bromo-pyrazole were then added. The mixture was
stirred at 80 °C for 2 h and quenched with 1 mL of H2O. The
aqueous phase was extracted 3 times with Et2O. The combined
organic phases were dried with Na2SO4, and the crude product was
obtained as a yellowish oil (99 mg). It was dissolved in 1 mL of 4 M
dioxane/HCl solution and stirred for 1 h at RT. After evaporation of
the solvent under reduced pressure, the crude product was solubilized
in ACN/H2O and purified by HPLC, eluting in a gradient of ACN/
H2O (yield: 5.2 mg, 7% for two steps).
1H NMR (300 MHz,
chloroform-d): δ 9.86 (s, 1H), 8.53 (s, 1H), 7.75−7.70 (m, 2H), 7.46
(s, 1H), and 7.33−7.29 (m, 2H). LCMS (method 2): Rt = 1.072 min;
MS (ESIpos): m/z [M + H]+ 263.0.
Compound 21: 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-1H-1,3-benzi-
midazole (Rabenzazole). Rabenzazole was commercially sourced
from Alfa Chemistry (Cat. No. ACM40341046) and used without
further purification.
Compound 22: 1-(1H-1,3-Benzodiazol-2-yl)-3-methyl-1H-pyra-
zol-5-amine. Compound 22 was commercially sourced from MolPort
SIA (Cat. No. MP-000-490-277) and used without further
purification.
Compound 23: 1-(1H-1,3-Benzodiazol-2-yl)-3-methyl-4-phenyl-
1H-pyrazol-5-amine. Compound 23 was commercially sourced from
MolPort SIA (Cat. No. MP-000-476-058) and used without further
purification.
Compound 24: 1-(Benzo[d]thiazol-2-yl)-3-methyl-4-phenyl-1H-
pyrazol-5-ol. 48 mg of (0.29 mmol) 2-hydrazinobenzothiazole was
solubilized in 4 mL of EtOH. After addition of 50 mg of (0.23 mmol)
ethyl-2-phenylacetoacetate, the reaction mixture was stirred at 80 °C
for 2 h. EtOH was evaporated, and the crude product was solubilized
in ACN/H2O and purified by HPLC, eluting in a gradient of ACN/
H2O (yield: 16 mg, 18%).
1H NMR (300 MHz, chloroform-d): δ
7.90−7.79 (m, 2H), 7.66−7.55 (m, 2H), 7.54−7.42 (m, 3H), 7.42−
7.28 (m, 2H), and 2.45 (s, 3H). 13C NMR (75 MHz, CDCl3): δ
152.2, 148.5, 142.6, 141.9, 139.6, 130.9, 128.5, 127.9, 126.9, 126.3,
124.7, 121.7, 121.2, and 14.5. LCMS (method 1): Rt = 1.418 min;
HRMS (ESIpos): m/z [M + H]+ calcd for C17H13N3OS, 308.0852;
found, 308.0852.
Compound 25: 3-Methyl-1-(1-methyl-1H-benzo[d]imidazol-2-
yl)-4-phenyl-1H-pyrazol-5-ol. 557.8 mg of (0.29 mmol) 2-hydrazi-
no-1-methyl-1H-benzimidazole hydrochloride was solubilized in 4 mL
of EtOH. 50 mg of (0.29 mmol) ethyl-2-acetylpent-4-enoate was
added, and the mixture was heated to 80 °C. After 2 h, EtOH was
removed under reduced pressure, and the crude product was
solubilized in 2 mL of ACN/H2O. The product was purified by
HPLC, eluting in a gradient of ACN/H2O (yield: 31.5 mg, 35%).
1H
NMR (300 MHz, chloroform-d): δ 8.77 (s, 1H), 7.68−7.57 (m, 3H),
7.48−7.34 (m, 5H), 7.31−7.25 (m, 1H), 4.29 (s, 3H), and 2.44 (s,
3H). 13C NMR (75 MHz, chloroform-d): δ 155.5, 151.3, 145.1, 136.4,
133.1, 131.6, 128.4, 127.8, 125.9, 123.8, 123.1, 117.0, 109.6, 101.5,
32.7, and 14.6. LCMS (method 1): Rt = 1.438 min; HRMS (ESIpos):
m/z [M + H]+ calcd for C18H16N4O, 305.1397; found, 305.1394.
Compound 26: 3-Methyl-4-phenyl-1-(pyridin-2-yl)-1H-pyrazol-5-
ol. 13.3 mg of (0.13 mmol) 2-hydrazinopyridine was solubilized in 0.5
mL of MeOH. After addition of 25 mg of (0.13 mmol) ethyl-2-
benzylactoacetate, the reaction mixture was stirred at 45 °C for 2 h.
MeOH was evaporated, and the crude product was purified by HPLC,
eluting in a gradient of ACN/H2O (yield: 11 mg, 36%).
1H NMR
(300 MHz, DMSO-d6): δ 12.39 (s, 1H), 8.63−8.35 (m, 2H), 8.02−
7.87 (m, 1H), 7.60 (d, J = 6.4 Hz, 2H), 7.44−7.31 (m, 2H), 7.31−
7.14 (m, 2H), and 2.38 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ
160.9, 148.6, 147.8, 146.0, 139.3, 132.7, 128.5, 127.7, 127.7, 125.8,
120.6, 111.9, and 12.6. LCMS (method 1): Rt = 1.783 min; HRMS
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(ESIpos): m/z [M + H]+ calcd for C15H13N3O, 252.1131; found,
252.1137.
Compound 27: 4-Benzyl-3-methyl-1-(pyridin-2-yl)-1H-pyrazol-5-
ol. 19.8 mg of (0.18 mmol) 2-hydrazinopyridine was solubilized in 4
mL of EtOH. After addition of 40 mg of (0.18 mmol) ethyl-2-
benzylactoacetate, the reaction mixture was stirred at 80 °C for 2 h.
EtOH was evaporated, and the crude product was purified by HPLC,
eluting in a gradient of ACN/H2O (yield: 38.8 mg, 80%).
1H NMR
(300 MHz, chloroform-d): δ 8.24 (d, J = 4.9 Hz, 1H), 7.93 (d, J = 8.4
Hz, 1H), 7.88−7.79 (m, 1H), 7.33−7.29 (m, 4H), 7.25−7.16 (m,
1H), 7.14−7.07 (m, 1H), 3.74 (s, 2H), and 2.17 (s, 3H). 13C NMR
(75 MHz, chloroform-d): δ 154.7, 153.5, 150.7, 145.2, 140.6, 139.7,
128.3, 128.1, 125.8, 119.5, 111.6, 100.1, 27.5, and 12.8. LCMS
(method 1): Rt = 1.429 min; HRMS (ESIpos): m/z [M + H]
+ calcd
for C16H15N3O, 266.1288; found, 266.1276.
Compound 28: 4-Allyl-3-methyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol.
32 mg of (0.29 mmol) 2-hydrazinopyridine was solubilized in 4 mL of
EtOH. 50 mg of (0.29 mmol) ethyl-2-acetylpent-4-enoate was added,
and the mixture was heated to 80 °C. After 2 h, EtOH was removed
under reduced pressure, and the crude product was solubilized in 2
mL of ACN/H2O. The product was purified by HPLC, eluting in a
gradient of ACN/H2O (yield: 15 mg, 24%).
1H NMR (300 MHz,
chloroform-d): δ 8.24 (d, J = 4.96 Hz, 1H), 7.91 (d, J = 8.32 Hz, 1H),
7.87−7.79 (m, 1H), 7.13−7.08 (m, 1H), 5.92 (ddt, J = 16.1, 9.9, 5.9
Hz, 1H), 5.11−4.99 (m, 2H), 3.12 (dt, J = 5.9, 1.8 Hz, 2H), and 2.21
(s, 3H). 13C NMR (75 MHz, chloroform-d): δ 154.2, 153.6, 150.8,
145.2, 139.6, 136.0, 119.3, 114.5, 111.5, 98.2, 25.7, and 12.7. LCMS
(method 1): Rt = 1.329 min; HRMS (ESIpos): m/z [M + H]
+ calcd
for C18H16N4O, 305.1397; found, 305.1383.
Compound 29: 1-(6-Chloropyridazin-3-yl)-3-methyl-4-phenyl-
1H-pyrazol-5-ol. 35 mg of (0.24 mmol) 3-chloro-6-hydrazino-
pyridazine was solubilized in 4 mL of EtOH at RT. After addition
of 50 mg of (0.24 mmol) ethyl-2-phenylacetoacetate, the reaction
mixture was stirred at 80 °C for 2 h. EtOH was evaporated, and the
crude product was solubilized in ACN/H2O and purified by HPLC,
eluting in a gradient of ACN/H2O (yield: 10 mg, 14%).
1H NMR
(300 MHz, chloroform-d): δ 8.19 (d, J = 7.0 Hz, 1H), 7.68 (d, J = 9.5
Hz, 1H), 7.56 (d, J = 7.6 Hz, 2H), 7.48−7.40 (m, 2H), 7.31 (d, J =
7.3 Hz, 1H), and 2.43 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ
161.9, 152.4, 151.0, 148.7, 132.0, 131.3, 128.6, 127.8, 126.1, 119.8,
104.1, and 12.7. LCMS (method 1): Rt = 1.314 min; HRMS
(ESIpos): m/z [M + H]+ calcd for C14H11N4O, 287.0694; found,
287.0692.
Compound 30: 2-(5-Hydroxy-3-methyl-4-phenyl-1H-pyrazol-1-
yl)-1H-benzo[d]imidazole-5-carboxylic Acid in Two Steps. 20 mg of
(0.1 mmol) of methyl 2-hydrazineyl-1H-benzo[d]imidazole-5-carbox-
ylate was solubilized in 0.5 mL of MeOH at RT. After the addition of
20 mg of (0.1 mmol) ethyl-2-phenylacetoacetate, the reaction mixture
was stirred at 45 °C for 2 h. MeOH was evaporated under reduced
pressure, the crude methyl 2-(5-hydroxy-3-methyl-4-phenyl-1H-
pyrazol-1-yl)-1H-benzo[d]imidazole-5-carboxylate was dissolved in 1
mL of THF and 1 mL of a 1 M LiOH solution was added at RT. After
saponification, the crude product was solubilized in ACN/H2O and
purified by HPLC, eluting in a gradient of ACN/H2O (yield: 2 mg,
14%). LCMS (method 2): Rt = 1.022 min; MS (ESIpos): m/z [M +
H]+ 335.1.
Protein Purification. Catalytic domains of KDM4 isoforms were
expressed either as N-terminal hexahistidine (His6)-tagged proteins
(KDM4A/E) or as N-terminal thioredoxin/His6-tagged fusion
proteins (KDM4D). KDM4A (residues 1-359) was expressed from
the pQTEV expression vector. The plasmid (pNic28-Bsa4-based)
encoding KDM4E residues 1-337 was a gift from the Structural
Genomics Consortium (Oxford, UK). KDM4D residues 1-378 was
expressed from the pNH-TrxT expression vector. Proteins were
expressed in Escherichia coli strain BL21 (DE3)-R3 containing the
pRARE2 plasmid, purified using Ni2+ affinity and S200 gel filtration
chromatography, and processed with TEV protease for affinity tag
removal exactly as previously described.24,32,35
Enzyme Activity Assays. The KDM4 enzyme activity was
measured by a fluorescence-based, formaldehyde dehydrogenase
(FDH)-coupled enzyme assay36 and by a calf thymus histone
(CTH)-ELISA,18 as previously described. The processed data were
analyzed for IC50 values using either the log (inhibitor) vs response
(with variable slope) or biphasic dose−response models in GraphPad
Prism 5.01.
Mechanism of Action Studies. The FDH-based KDM4 activity
assay was used to calculate the kinetic values of Km and Vmax for the
H3K9me3 peptide substrate and for the α-KG cofactor using initial
velocity data and the Michaelis−Menten fitting model of GraphPad
Prism 5.01. Fitting procedures and kinetic constant determinations
were then repeated on the initial velocity data collected in the
presence of either 1, 5, 10, or 20 μM of the KDM4 inhibitor,
compound 15. The α-KG-competitive KDM4 inhibitor 2,4-PDCA
was characterized in parallel as a validated control. Double reciprocal
plots of initial velocity data were generated in tandem to serve as
qualitative assessments of enzyme inhibition.
Protein Crystallization and Ligand-Soaking Experiments.
Crystals of KDM4A were grown using the hanging-drop vapor-
diffusion method at 277 K. The reservoir solution comprised 20% (w/
v) PEG 3350, 10 mM NiCl2, and 0.1 M citrate buffer pH 5.5;
KDM4A was concentrated to 11.5 mg/mL in a solution comprising
0.5 M NaCl, 5% (v/v) glycerol, 1 mM TCEP, and 10 mM HEPES pH
7.5. Crystallization drops were prepared by mixing ice-cold protein
solution with ice-cold reservoir solution at a 2:1 ratio of protein-to-
reservoir solution. Crystallization was accelerated by micro-seeding
using a cat whisker for seed transfer. Inhibitors (compounds 26 and
30) were soaked overnight into KDM4A crystals by introducing a 0.3
μL volume of inhibitor stock solution (100 mM ligand in 100%
DMSO) to a 2.2 μL drop containing crystals plus reservoir solution
[12 mM final ligand concentration, 12% (v/v) DMSO]. The cryo-
solutions comprised reservoir solution plus ethylene glycol (EDO),
increased step-wise by 5% increments, from an initial concentration of
5% (v/v) EDO up to a final concentration of 20% (v/v). Crystals
were immersed for 1 s in each ice-cold cryo-solution and carefully
transferred to higher EDO concentrations before flash cooling in
liquid nitrogen.
KDM4D crystals were grown using the sitting-drop vapor-diffusion
method at 291 K. First, KDM4D was concentrated to 19 mg/mL in a
solution comprising 0.5 M NaCl, 5% (v/v) glycerol, 1 mM TCEP,
and 10 mM HEPES buffer pH 7.5. The reservoir solution comprised
24% (w/v) PEG 3350, 180 mM ammonium sulfate, and 0.1 M
HEPES pH 7.0. A Gryphon crystallization robot (Art Robbins
Instruments) was used to mix 0.4 μL of the reservoir solution with an
equal volume of protein solution on the surface of a 96-well low
profile Intelli-Plate (Art Robbins Instruments). KDM4D crystals were
presoaked for 10 min directly in well solutions by addition of 10 mM
NiCl2 and subsequently transferred to a ligand-soaking solution
comprising the reservoir solution plus 50 mM compound 1 and a total
of 5% (v/v) DMSO. The crystals were soaked overnight at 18 °C.
Finally, the soaked crystals were cryo-protected by quick immersion
into the reservoir solution supplemented with 20% EDO and flash
cooled in liquid nitrogen.
Energy-Dispersive Fluorescence Spectra. Energy-dispersive
fluorescence spectra were acquired at room temperature on the MX
beamline BL14.137 of the BESSY II synchrotron, operated by the
Helmholtz-Zentrum für Materialien und Energie in Berlin, Germany.
KDM4D crystals were presoaked in NiCl2, washed twice in the
reservoir solution without Ni2+ ions, mounted on nylon loops, and
inserted into capillaries for measurement. The peaks were identified
using XFEplot (https://www.helmholtz-berlin.de/forschung/oe/ps/
macromolecular-crystallography/hzb-mx-software/xfeplot/index_en.
html). The energy-dispersive fluorescence spectra were measured at
three different positions within a crystal (2 s count time). The crystals
were subsequently unmounted and gently transferred to the KDM4D
ligand-soaking solution and incubated overnight. As a control, Ni2+-
saturated KDM4D crystals were soaked overnight as indicated above,
but in the reservoir solution supplemented with 5% (v/v) DMSO.
The following day, the crystals were washed twice in a non-
supplemented reservoir solution and measured as described above for
initial measurements. Single-crystal measurements were averaged and
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c00693
J. Med. Chem. 2021, 64, 14266−14282
14279
separately normalized to the intensity of the highest observable peak
(corresponding to structural Zn2+ ions in the case of KDM4D), both
before and after soaking (the amount of Zn2+ ions in KDM4D crystals
is assumed to be unaffected by ligand soaking).
Data Collection, Processing, Structure Determination, and
Refinement. X-ray diffraction data were collected on the MX
beamline BL14.137 at BESSY II in Berlin using a PILATUS 6M
detector. Data were integrated and scaled using the XDSAPP
software.38,39 The structures were solved by molecular replacement
using the existing models of KDM4 enzymes (PDB-IDs 3PDQ for
KDM4A and 4HON for KDM4D) and the program Phaser.40 The
updated model (molecular replacement solution) was initially refined
with Refmac41 and subsequently by phenix.refine.42 The final model
was generated after cycles of manual adjustment using Coot,43
validated, and deposited into the Protein Data Bank (PDB-IDs 6G5W
and 6G5X).
Cell Culture. Human primary PCa cell lines (LnCaP and DU145)
and the non-disease control, human prostate epithelial cell line
(HuPrEC, Merck Millipore), were propagated according to
established protocols, either from ATCC (LnCaP, DU145) or from
Merck Millipore (HuPrEC).
Cytotoxicity Assays. Cytotoxicity of selected KDM4 inhibitors
against PCa cell lines and against a HuPrEC control cell line was
assessed by the alamarBlue assay as previously described.18
Reporter Gene Assay. A reporter gene construct was generated
by PCR amplification of the PSA promoter and enhancer regions
from plasmid pDRIVE5Lucia-PSA-hPSA (Invivogen, San Diego, CA)
using forward primer: 5′-attggtaccCCTCTAGAAATCTAGCTGA-
TATAG-3′ and reverse primer: 5′-gttctcgaGGTGACA-
CAGCTCTCCGGGTG-3′. The PCR product was digested with
KpnI/XhoI and ligated into the similarly-digested pGL4.10 reporter
vector (Promega, Madison, WI). The resulting construct (PSA-
pGL4.10) yielded a firefly luciferase reporter gene under the control
of the PSA promoter. AR-positive LnCaP cells were used for
transfection experiments. A total of 14,000 cells were seeded into 10
replicate wells of a 96-well plate containing 100 μL of RPMI medium
plus 10% FBS (Thermo Fisher Scientific, Waltham, MA) and 1×
MEM non-essential amino acids. Cells were grown for 48 h at 37 °C
and 5% CO2 before being transfected with 100 ng of either PSA-
pGL4.10 or empty vector using Lipofectamine LTX and the Plus
reagent (Thermo Fisher Scientific, Waltham, MA), according to the
manufacturer’s protocol. The transfected cells were grown for 24 h
prior to the addition of KDM4 inhibitors or the addition of DMSO
alone [0.5% (v/v)] as vehicle control. Each test condition was
repeated in biological replicates of eight. Cells were then grown under
test conditions for an additional 48 h prior to lysis and measurement
of luminescence. Cell lysis and luminescence measurements were
performed using a Beetle-Juice luminescence kit (P.J.K. GmbH,
Kleinblittersdorf, DE) on a FluoStar Optima plate reader (BMG
Labtech, Ortenberg, DE).
Gene Expression Analysis by qPCR. LnCaP cells were grown in
triplicate wells of a 6-well plate at 37 °C and 5% CO2 until reaching
75% confluency. At this point, compounds (ML324, compound 15, or
DMSO control) were added to the growth media, and the cells were
grown for an additional 48 h prior to RNA extraction and downstream
processing. Where applicable, DMSO was present at 0.5% (v/v).
Culture media were then aspirated and cells were lysed in Trizol Plus
reagent (Life Technologies). The resulting RNA was purified using
the PureLink RNA Mini Kit (Life Technologies) including on-column
digestion with DNAse by the PureLink DNAse Kit (Life
Technologies). RNA quality was assessed by agarose gel electro-
phoresis and quantified by absorbance readings at 260 nm using a
Nanodrop instrument. Complementary DNA (cDNA) was synthe-
sized with the High Capacity RNA-to-cDNA kit (Applied
Biosystems) containing random octamer and oligo (dT) primers.
PCR was performed on a Bio-Rad CFX96 thermocycler instrument.
Expression of PSA was measured relative to the housekeeping gene,
hypoxanthine phosphoribosyltransferase 1 (HPRT1), using primers:
PSA Fwd: 5′-AAGCTGGAGGCACAACGCACC-3′; PSA-Rev: 5′-
CCTCCTTGGCTCACAGCCTTCTC-3′; HPRT1 Fwd: 5′-
GCTGAGGATTTGGAAAGGGTG-3′; and HPRT1 Rev: 5′-GCTA-
CAATGTGATGGCCTCC-3′. Gene amplification was measured
using the Power SybrGreen PCR Master Mix (Applied Biosystems)
and analyzed by thermal melting curves as well as by agarose gel
electrophoresis after PCR cycling. Fold differences in gene expression
were calculated by the ΔΔCt method44,45 and analyzed for statistical
significance using GraphPad Prism 5.01 software.
Chromatin Analysis by Western Blot. LnCaP cells were grown
and treated with the inhibitor as described below for Nu-ELISA
experiments. Cells were then lysed and chromatin purified with a
Histone Purification Mini Kit (Active Motif, Carlsbad, CA), according
to the manufacturer’s protocol. The resulting chromatin (2 μg from
each test condition) was loaded on 4−20% gradient Mini-PROTEAN
TGX polyacrylamide gels (Bio-Rad) and separated by SDS-PAGE
electrophoresis. Western blot analysis was performed with a
monoclonal antibody specific for H3K9me3 (Abcam Ab#6001). A
second antibody (BioVision #3624) specific for a non-epigenetic
epitope in histone H4 was used as a loading control. An HRP-
conjugated mouse anti-rabbit IgG was used as a secondary detection
antibody (Cell Signaling Technology, Inc.). The band density was
measured by densitometry and quantified with ImageJ software.46 The
changes in chromatin methylation were evaluated relative to untreated
cells grown in media alone.
Chromatin Analysis by Nu-ELISA. Cells (LnCaP and DU145
cell lines) were grown in triplicate wells of a 6-well plate. Upon
reaching 75% confluence, the media was changed and replaced with
inhibitor-supplemented media. Cells were then grown for an
additional 48 h. The medium was then removed, and plates were
washed twice with PBS before freezing in liquid nitrogen and storage
at −80 °C until further analysis. After a freeze−thaw lytic cycle, the
cell material was resuspended in MNase buffer (5 mM NaPO4 pH 7.0
and 0.025 mM CaCl2) and digested with 2 units of MNase (Sigma-
Aldrich, St. Louis, MO) for 12 min at 37 °C. The digested material
containing nucleosomes was coated into replicate wells (n = 9) of a
96-well ELISA plate (Nunc) and incubated overnight at 4 °C. The
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